Navigation Links
Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
Date:3/19/2012

BEDMINSTER, N.J., March 19, 2012 /PRNewswire/ -- Nautilus Neurosciences announced today that their Canadian promotional partner, Tribute Pharmaceuticals, a wholly owned subsidiary of Stellar Pharmaceuticals, was granted a Notice of Compliance (NOC) approval from Health Canada for CAMBIA® (diclofenac potassium for oral solution) in the treatment of acute migraine with or without aura in adults. CAMBIA® is expected to be launched in Canada during the second half of 2012. CAMBIA® has been available to patients in the United States since May 2010.

Nautilus Neurosciences has exclusive marketing rights for CAMBIA® in the United States and Canada, which they obtained from APR, a Swiss drug delivery and drug development company. Patents have been granted that protect the product in the United States through 2026.

"We congratulate our partners at Tribute Pharmaceuticals on the Health Canada approval and look forward to continuing to work with them on the Canadian launch of CAMBIA®. We are excited that CAMBIA® will be available as a treatment option for physicians and patients in Canada," said William Maichle, the CEO of Nautilus Neurosciences. Mr. Maichle highlighted, "With CAMBIA® now approved in both the United States and Canada, this marks another major milestone in the evolution of Nautilus to a best-in-class neurology-focused specialty pharmaceutical company."

Mr. Maichle added, "Looking forward, our strategy is to build an increasingly valuable company through the addition of complementary neurology-targeted therapies through in-licensing and acquisition opportunities. Mr. Maichle concluded, "[I] expect Nautilus Neurosciences to experience record growth in 2012 as CAMBIA® continues to fill an important unmet need for patients suffering from the debilitating effects of migraine."

About CAMBIA®

CAMBIA® (diclofenac potassium for oral solution) is the lead product fro
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
2. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
3. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
4. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
5. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
7. Proteonomix Announces a Private Placement of $3.8 Million
8. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
9. ARUP Laboratories Announces Creation of Business Innovations Division
10. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
11. Regeneron Announces March 2012 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... SILVER SPRING, Md. , Dec. 17, 2014 /PRNewswire/ ... today two senior executive promotions as well as changes ... Senior Executive Promotions United ... Ph.D. to President and Co-Chief Executive Officer and ... Chief Operating Officer.  In connection with these promotions, Dr. ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... December 15, 2014 METTLER TOLEDO ... PVM tool, ParticleView V19 with PVM technology ... probe-based particle vision and measurement tool continuously captures ... conditions. ParticleView V19 then automatically prepares a report ... particle size and concentration changes. This compelling blend ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... California. , Dynal : 400+ employees worldwide, 87 in ... Norway. Brown Deer, Wis. California-based ... ASA , whose U.S. operations are based in Brown ... million. , ,Invitrogen has considered the acquisition since ...
... venture capital performance in the U.S. during 2004. , ,We ... share of this investment as well as how the life science ... detailed look at how the life science industry in the Midwest ... report. , ,Still, I was able to ferret out some ...
... written about the important impact that generic pharmaceutical drugs ... Their rise and growth spurs Big Pharma to invest ... Americans not having any kind of medical health insurance ... medicines from Canada being rapidly shut by U.S. pharmaceutical ...
Cached Biology Technology:Invitrogen to buy Norwegian biotech with operations in Brown Deer 2Midwest VC investment up in 2004, but number of deals down 2Midwest VC investment up in 2004, but number of deals down 3Pharmas will be forced into generic-drug strategy 2Pharmas will be forced into generic-drug strategy 3
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... 2013, New York, NY Ludwig researchers have elucidated a ... metabolize glucose to generate the energy and raw materials ... in Cell Metabolism , the Ludwig Cancer Research ... harnesses the mechanism to resist targeted therapies that should ...
... steer clear of dirt but their wild cousins can,t be ... a result. A study of wild mice has shown ... material and droppings left by other mice. Choosing a ... an increased risk of disease from other animals, dirt, the findings ...
... that individual "molecular muscles" within cells respond to different types ... the environment and appropriately adapt their shapes and activities. ... the journal Nature Materials , specifically sheds light on ... A computer model the researchers developed, they add, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
... Protein Solubility Service, We deliversoluble protein ... SOS technology yields the best soluble protein ... on each clone submitted , Powerful results ... new protein Solubility Optimization Service (SOS) uses ...
... Multi-Disciplinary Team The ... is a stand-alone work center dedicated ... array manufacturing. The facilitys experienced project ... Planning and Marketing professionals, work closely ...
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... commonly used technique for studying protein function ... on SDS-PAGE and transferred to a membrane ... are probed with specific antibodies. Unlike nucleic ... Southern and Northern blots, it has been ...
Biology Products: